IBDEI0WO ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15882,2)
 ;;=^295322
 ;;^UTILITY(U,$J,358.3,15883,0)
 ;;=V17.3^^81^949^16
 ;;^UTILITY(U,$J,358.3,15883,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15883,1,4,0)
 ;;=4^V17.3
 ;;^UTILITY(U,$J,358.3,15883,1,5,0)
 ;;=5^Family h/o Ischemic Heart Dis
 ;;^UTILITY(U,$J,358.3,15883,2)
 ;;=^295305
 ;;^UTILITY(U,$J,358.3,15884,0)
 ;;=V16.6^^81^949^17
 ;;^UTILITY(U,$J,358.3,15884,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15884,1,4,0)
 ;;=4^V16.6
 ;;^UTILITY(U,$J,358.3,15884,1,5,0)
 ;;=5^Family h/o Leukemia
 ;;^UTILITY(U,$J,358.3,15884,2)
 ;;=^295298
 ;;^UTILITY(U,$J,358.3,15885,0)
 ;;=V18.61^^81^949^19
 ;;^UTILITY(U,$J,358.3,15885,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15885,1,4,0)
 ;;=4^V18.61
 ;;^UTILITY(U,$J,358.3,15885,1,5,0)
 ;;=5^Family h/o Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,15885,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,15886,0)
 ;;=V17.0^^81^949^20
 ;;^UTILITY(U,$J,358.3,15886,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15886,1,4,0)
 ;;=4^V17.0
 ;;^UTILITY(U,$J,358.3,15886,1,5,0)
 ;;=5^Family h/o Psychiatric Condition
 ;;^UTILITY(U,$J,358.3,15886,2)
 ;;=^295302
 ;;^UTILITY(U,$J,358.3,15887,0)
 ;;=V19.4^^81^949^21
 ;;^UTILITY(U,$J,358.3,15887,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15887,1,4,0)
 ;;=4^V19.4
 ;;^UTILITY(U,$J,358.3,15887,1,5,0)
 ;;=5^Family h/o Skin Condition
 ;;^UTILITY(U,$J,358.3,15887,2)
 ;;=^295324
 ;;^UTILITY(U,$J,358.3,15888,0)
 ;;=V17.1^^81^949^22
 ;;^UTILITY(U,$J,358.3,15888,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15888,1,4,0)
 ;;=4^V17.1
 ;;^UTILITY(U,$J,358.3,15888,1,5,0)
 ;;=5^Family h/o Stroke (CVA)
 ;;^UTILITY(U,$J,358.3,15888,2)
 ;;=^295303
 ;;^UTILITY(U,$J,358.3,15889,0)
 ;;=V16.8^^81^949^12
 ;;^UTILITY(U,$J,358.3,15889,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15889,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,15889,1,5,0)
 ;;=5^Family h/o Cancer,Other Specified
 ;;^UTILITY(U,$J,358.3,15889,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,15890,0)
 ;;=V11.1^^81^949^24
 ;;^UTILITY(U,$J,358.3,15890,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15890,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,15890,1,5,0)
 ;;=5^Hx of Affective Disorder
 ;;^UTILITY(U,$J,358.3,15890,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,15891,0)
 ;;=V15.89^^81^949^46
 ;;^UTILITY(U,$J,358.3,15891,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15891,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,15891,1,5,0)
 ;;=5^Hx of Persian Gulf Region Exposure
 ;;^UTILITY(U,$J,358.3,15891,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,15892,0)
 ;;=V11.3^^81^949^25
 ;;^UTILITY(U,$J,358.3,15892,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15892,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,15892,1,5,0)
 ;;=5^Hx of Alcoholism
 ;;^UTILITY(U,$J,358.3,15892,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,15893,0)
 ;;=V15.07^^81^949^26
 ;;^UTILITY(U,$J,358.3,15893,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15893,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,15893,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,15893,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,15894,0)
 ;;=V13.4^^81^949^27
 ;;^UTILITY(U,$J,358.3,15894,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15894,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,15894,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,15894,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,15895,0)
 ;;=V12.72^^81^949^31
 ;;^UTILITY(U,$J,358.3,15895,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15895,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,15895,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,15895,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,15896,0)
 ;;=V12.59^^81^949^30
 ;;^UTILITY(U,$J,358.3,15896,1,0)
 ;;=^358.31IA^5^2
 ;;
 ;;$END ROU IBDEI0WO
